<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The differentiation between hereditary and <z:hpo ids='HP_0003745'>sporadic</z:hpo> microsatellite-unstable (MSI-H) <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> is a crucial step in <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> diagnostics </plain></SENT>
<SENT sid="1" pm="."><plain>Within MSI-H <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e>, the BRAF V600E mutation is strongly associated with <z:hpo ids='HP_0003745'>sporadic</z:hpo> origin </plain></SENT>
<SENT sid="2" pm="."><plain>We here asked whether BRAF V600E-specific immunohistochemistry (clone VE1) is helpful in separating <z:hpo ids='HP_0003745'>sporadic</z:hpo> from <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e>-associated MSI-H <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>To that end, we performed VE1 immunohistochemistry and BRAF sequencing in a series of 91 MSI-H <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> specimens from patients tested for <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Concordance of VE1 immunohistochemistry and molecular BRAF mutation status was observed in 90 out of 91 (98.9%) MSI-H samples </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> eleven <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> classified as BRAF V600E mutation-positive by Sanger sequencing were immuno-positive, and 79 (98.8%) out of 80 tumors classified as BRAF <z:mp ids='MP_0002169'>wild type</z:mp> showed negative staining </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> VE1-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> were MLH1 and PMS2-negative by immunohistochemistry </plain></SENT>
<SENT sid="7" pm="."><plain>None of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> from MMR gene germline mutation carriers (n=28) displayed positive VE1 staining, indicating that BRAF V600E mutation-specific immunostaining has a low risk of excluding <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e> patients from germline mutation analysis </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, implementation of VE1 immunohistochemistry was able to detect BRAF mutated MSI-H <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> with a sensitivity of 100% and a specificity of 98.7% </plain></SENT>
<SENT sid="9" pm="."><plain>Among MLH1-negative <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e>, the rate of VE1-positive lesions was 21%, offering the exclusion of these patients from MMR germ line testing </plain></SENT>
<SENT sid="10" pm="."><plain>We therefore suggest the integration of VE1 immunohistochemistry into the diagnostic panel of <z:e sem="disease" ids="C0009405" disease_type="Neoplastic Process" abbrv="">Lynch syndrome</z:e>. Â© 2013 Wiley Periodicals, Inc </plain></SENT>
</text></document>